Skip to main content

JHU research led to a breakthrough for allergy vaccines. Now they’re taking aim at cancer – Technical.ly Baltimore

By November 12, 2015News
johns-hopkins-logo

johns-hopkins-logo

Johns Hopkins tech transfer is at the heart of a new agreement meant to bolster the development of a DNA-based vaccine for allergies.

Formally, Rockville-based Immunomic Therapeutics inked a licensing deal with Astellas Pharma, which will develop the allergy vaccine. Through the deal, Immunomic will receive an upfront payment of $300 million, and is entitled to 10 percent royalties from vaccine products developed. Astellas, a Japan-based pharmaceutical giant, gets the right to produce the vaccine worldwide.

{iframe}http://technical.ly/baltimore/2015/11/11/jhu-research-immunomic-therapeutics-allergies-cancer/?utm_source=Technical.ly&utm_campaign=ede9fe0b00-BaltimoreDailyNewsletter&utm_medium=email&utm_term=0_dde0db1108-ede9fe0b00-408421769{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.